CAR-T Cell Therapy for Multiple Myeloma in China
Two NMPA-approved BCMA CAR-T products are available in China for relapsed or refractory multiple myeloma, for patients who have already tried at least three prior lines of therapy.
Who this is for
Multiple myeloma is a cancer of plasma cells in the bone marrow. Both approved products target BCMA (B-cell maturation antigen), a protein expressed on plasma cells, and are approved for fourth-line-or-later use: patients who have progressed after at least three prior treatment regimens, including at least one proteasome inhibitor (e.g., bortezomib) and one immunomodulatory drug (e.g., lenalidomide).
| Product | Manufacturer | Approved for |
|---|---|---|
| Fukesu (equecabtagene autoleucel) | IASO Biotherapeutics | R/R multiple myeloma, ≥3 prior lines incl. a proteasome inhibitor and an immunomodulatory drug |
| Saikaize (zevorcabtagene autoleucel) | CARsgen Therapeutics / Huadong Medicine | R/R multiple myeloma, ≥3 prior lines incl. a proteasome inhibitor and an immunomodulatory drug |
What makes myeloma CAR-T different
Because myeloma patients have usually been through multiple prior regimens, bone marrow reserve and overall fitness are assessed carefully before apheresis. Bridging therapy to control disease during the manufacturing window is common and is built into the treatment plan and quotation from the outset, not added as a surprise cost later.
Life after infusion
Most patients remain in China for several weeks of monitoring after infusion before traveling home with a detailed treatment passport and a follow-up schedule coordinated with their home hematologist, including monitoring for infection risk during the period of immune recovery.
Next step
Send your myeloma staging, M-protein/light-chain results and full prior-treatment history for a free eligibility review. Start your case review →